Antibody Titers against Mpox Virus after Vaccination
Angelica C Kottkamp, Marie I. Samanovic, Ralf Duerr, Aaron L. Oom, Hayley M. Belli, Jane R. Zucker, Jennifer B. Rosen, Mark J. Mulligan
Abstract
On May 11, 2023, the World Health Organization announced that mpox (formerly known as monkeypox) was no longer a public health emergency of international concern.However, at approximately the same time, a cluster of cases that included vaccine break-throughs 1 may have forecasted a potential for resurgence.The multicountry outbreak in 2022 disproportionately affected the LGBTQ+ community and persons with human immunodeficiency virus (HIV) infection. 2On August 9, 2022, Emergency Use Authorization was approved for a one-fifth dose of an intradermal regimen of the JYNNEOS vaccine (modified vaccinia Ankara, Bavarian Nordic [MVA-BN]) as a dose-sparing alternative to the two-dose subcutaneous regimen licensed in 2019.However, the intradermal route had not been studied in persons with HIV infection, and the durability of the antibody against mpox virus (MPXV) after MVA-BN vaccination was unknown.